Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
6-mercaptopurine (6-MP)
16%
Acute Lymphoblastic Leukemia
16%
Acute Myeloid Leukemia
50%
Acute Neurotoxicity
16%
Adverse Events
16%
Ara-C
16%
C-Pulse
16%
CNS Relapse
33%
Combination Chemotherapy
16%
Continuation Therapy
16%
Cytarabine
16%
Divided Dose
16%
Effective Treatment
16%
Event-free Survival
33%
Failure Pattern
16%
High-risk Factors
33%
High-risk Population
16%
Highly Effective
16%
Isolated CNS Relapse
16%
L-asparaginase
16%
Leucovorin
16%
Marrow
100%
Mercaptopurine
16%
Oral Methotrexate
100%
Precursor B-cell Acute Lymphoblastic Leukemia
100%
Relapse-free Survival
16%
Remission
33%
Repetitive Doses
16%
Second Malignancy
16%
Standard Risk
16%
Testicular Relapse
16%
VP16
33%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Acute Myeloid Leukemia
37%
Adverse Event
12%
Asparaginase
12%
Combination Chemotherapy
12%
Cytarabine
25%
Event Free Survival
25%
Folinic Acid
12%
High Risk Population
25%
Mercaptopurine
12%
Methotrexate
100%
Neurotoxicity
12%
Oral
100%
Outpatient
25%
Precursor
100%
Pulse Rate
12%
Recurrence Free Survival
12%
Repeated Drug Dose
12%
Second Cancer
12%
Single Drug Dose
12%
Immunology and Microbiology
Event Free Survival
25%
High Risk Population
25%
Methotrexate
100%
Precursor
100%
Pulse Rate
12%
Recurrence Free Survival
12%
Repeated Drug Dose
12%